Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pediatric FBS0701 study in transfusional iron overload
2011-001718-32Phase 2Terminated
- Sponsor
- FerroKin BioSciences
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferitazole in transfusional hemosiderosis and hemochromatosis (HH), sponsored by FerroKin BioSciences. Primary endpoints: Single-dose pharmacokinetics of FBS0701 and Safety, tolerability, and efficacy during chronic dosing. Started Mar 2012; status: terminated.
02
Drugs
deferitazole
03
Conditions
transfusional hemosiderosishemochromatosis (HH)
Beyond the preview
Go deeper on 2011-001718-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001718-32.